Artal Group’s Zymeworks ZYME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-450,000
Closed -$3.54M 143
2022
Q4
$3.54M Hold
450,000
0.2% 72
2022
Q3
$2.77M Hold
450,000
0.12% 80
2022
Q2
$2.38M Hold
450,000
0.13% 89
2022
Q1
$2.95M Hold
450,000
0.12% 104
2021
Q4
$7.38M Hold
450,000
0.2% 83
2021
Q3
$13.1M Hold
450,000
0.29% 70
2021
Q2
$15.6M Hold
450,000
0.32% 66
2021
Q1
$14.2M Buy
450,000
+100,000
+29% +$4.06M 0.25% 81
2020
Q4
$16.5M Buy
+350,000
New +$16.3M 0.36% 65

Other funds holding ZYME

Artal Group's ZYME Position: Q1 2023 in Review

Artal Group sold out of Zymeworks (ZYME) in Q1 2023, closing a stake of 450,000 shares — an estimated $3.54M sold.

Artal Group first reported a position in ZYME in Q4 2020 and held it in 9 quarters. The position peaked at $16.5M in Q4 2020. 115 funds tracked by Wall St. Rank hold ZYME as of Q1 2023.

  • Artal Group reported no remaining Zymeworks position as of Q1 2023 after selling out during the quarter.
  • Artal Group sold 450,000 Zymeworks shares in Q1 2023, an estimated $3.54M.
  • Artal Group first reported a position in Zymeworks in Q4 2020 and held it in 9 quarters.
  • Artal Group's Zymeworks position peaked at $16.5M in Q4 2020.
  • 115 funds tracked by Wall St. Rank held Zymeworks as of Q1 2023.

Based on Artal Group's 13F filing for Q1 2023, filed 12 May 2023.